Nanotechnology-based drug delivery platforms for erectile dysfunction: addressing efficacy, safety, and bioavailability concerns.

Autor: Hari Priya VM; Agroprocessing and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India., Ganapathy A A; Agroprocessing and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India., Veeran MG; Corporate Research and Development Centre (CRDC), HLL Lifecare Ltd, Akkulam, Thiruvananthapuram, India., Raphael M S; Department of Chemistry, Government College for Women, Thiruvananthapuram, India., Kumaran A; Agroprocessing and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram, India.; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Jazyk: angličtina
Zdroj: Pharmaceutical development and technology [Pharm Dev Technol] 2024 Nov; Vol. 29 (9), pp. 996-1015. Date of Electronic Publication: 2024 Oct 19.
DOI: 10.1080/10837450.2024.2414379
Abstrakt: Erectile dysfunction (ED), is a common and multidimensional sexual disorder, which comprises changes among any of the processes of the erectile response such as organic, relational, and psychological. However, both endocrine and nonendocrine causes of ED produce substantial health implications including depression and anxiety due to poor sexual performance, eventually affecting man's life eminence. Marginally invasive interventions following ED consist of lifestyle modifications, oral drugs, injections, vacuum erection devices, etc. Nevertheless, these conventional treatment regimens follow certain drawbacks such as efficacy and safety issues, and navigate to the development of novel therapeutic approaches such as nanomedicine for ED management. Nanotechnology-centred drug delivery platforms are being explored to minimize these limitations with better in vitro and in vivo effectiveness. Moreover, nanomedicine and nanocarrier-linked approaches are rapidly developing science in the nanoscale range, which contributes to site-specific delivery in a controlled manner and has generated considerable interest prominent to their potential to enhance bioavailability, decrease side effects, and avoidance of first-pass metabolism. This review provides an overview of recent discoveries regarding various nanocarriers and nano-delivery methods, along with current trends in the clinical aspects of ED. Additionally, strategies for clinical translation have been incorporated.
Databáze: MEDLINE